All-cause mortality and use of antithrombotics within 90 days of discharge in acutely ill medical patients

Summary

Conflicting evidence exists regarding predictors of and antithrombotic benefit on mortality in hospitalised acutely-ill medical patients. We compared mortality risk within 90 days post-discharge among medically ill patients who did and did not receive antithrombotics. This retrospective claims analysis included patients40 years with nonsurgical hospitalisation2 days between 2005 and 2009 using the HealthCore Integrated Research Database. Antithrombotic use (i.e. anticoagulants and antiplatelets) post-discharge was captured from pharmacy claims. All-cause mortality was determined from Social Security Death Index; cause of death was identified from National Death Index database. Kaplan-Meier survival curves were generated and hazard ratios (HR) for mortality risk were estimated using Cox proportional hazards models. Patients prescribed anticoagulants or antiplatelets post-discharge had lower risk of short-term mortality. For the anticoagulant model, the most significant predictors of mortality were malignant/benign neoplasms (hazard ratio [HR] 1.6, 95 % confidence interval [CI] 1.5–1.7), liver disease (HR 1.6, 95 % CI 1.5–1.7), anticoagulant omission (HR 1.6, 95 % CI 1.4–1.8), gastrointestinal or respiratory tract intubations (HR 1.5, 95 % CI 1.3–1.7), and blood dyscrasias (HR 1.4, 95 % CI 1.4–1.5). For the antiplatelet model, the most significant predictors of mortality were antiplatelet omission (HR 3.7, 95 % CI 3.3–4.1), liver disease (HR 1.6, 95 % CI 1.4–1.7), malignant/benign neoplasms (HR 1.6, 95 % CI 1.5–1.6), gastrointestinal or respiratory tract intubations (HR 1.5, 95 % CI 1.3–1.7), and blood dyscrasias (HR 1.4, 95 % CI 1.4–1.5). These mortality risk factors may guide future studies assessing potential benefits of antithrombotics in specific subsets of patients.

Keywords

Mortality - medical patients - risk factors - anticoagulants - antiplatelet agents

• References

• 1 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 2 Prandoni P, Lensing AWA, Cogo A. et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med 1996; 125: 1-7.
• 3 Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalisation. J Am Med Assoc 2003; 290: 1868-1874.
• 4 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30.
• 5 Piazza G, Goldhaber SZ. Physician alerts to prevent venous thromboembolism. J Thromb Thrombolysis 2010; 30: 1-6.
• 6 Mahan CE, Borrego ME, Woersching AL. et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012; 108: 291-302.
• 7 Spyropoulos AC, Anderson Jr FA, Fitzgerald G. et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-714.
• 8 Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health Syst Pharm 2012; 69: 2174-2190.
• 9 Kakkar AK, Cimminiello C, Goldhaber SZ. et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med 2011; 365: 2463-2472.
• 10 Halkin H, Goldberg J, Modan M. et al. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 561-565.
• 11 Dentali F, Douketis JD, Gianni M. et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278-288.
• 12 Gärdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet 1996; 347: 1357-1361.
• 13 Second International Study of Infarct Survival Study Group.. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
• 14 Third International Study of Infarct Survival Collaborative Group.. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-770.
• 15 International Stroke Trial Collaborative Group.. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 1997; 349: 1569-1581.
• 16 Wallentin L, Becker RC, Budai A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 17 Hill ME, Rosenwaike I. The Social Security Administration’s Death Master File: the completeness of death reporting at older ages. Soc Secur Bull 2001; 2002 64: 45-51.
• 18 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
• 19 Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 (23) (Suppl. 01) I17-I21.
• 20 Becattini C, Agnelli G, Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.
• 21 Simes J, Becattini C, Agnelli G. et al. Aspirin for the Prevention of Recurrent Venous Thromboembolism: the INSPIRE Collaboration. Circulation 2014; 130: 1062-1071.